AlgovestIQCatalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
Upcoming reporting date available for this company.
Momentum 71/100 and sentiment — before the next covered event.
Updated Sep 6, 2026 · Sentiment 10.43%
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | — | -$1.11 | -$1.18 | -6.3% | $16.37M | $490K |
| May 7, 2026 | — | -$0.87 | -$0.91 | -4.6% | $10.98M | $31.74M |
| Feb 24, 2026 | — | -$1.13 | -$0.10 | +91.2% | $11.67M | $114.11M |
| Nov 4, 2025 | — | -$0.98 | -$1.10 | -12.2% | $13.22M | $9.7M |
| Aug 5, 2025 | — | -$1.04 | -$1.00 | +3.8% | $11.54M | $8.47M |
| May 6, 2025 | — | -$1.11 | -$1.24 | -11.7% | $15.52M | $7.47M |
| Feb 25, 2025 | — | -$1.25 | -$1.09 | +12.8% | $16.47M | $30.07M |
| Nov 5, 2024 | — | -$1.13 | -$1.17 | -3.5% | $15.12M | $14.27M |
Wall Street consensus, rating distribution, and the current 12-month target range.
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Next known earnings or reporting date.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
Recent company coverage, scored where source sentiment is available.
CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 10 affordable biotech stocks to buy right now. On July 8, Alec Stranahan from Bank of America Securities reaffirmed his Buy rating for Beam Therapeutics Inc. (NASDAQ:BEAM), following a favorable resolution announced by Prime Medicine regarding its arbitration with Beam. Stranahan forecasted a target price of $47, […]
Prime Medicine, Inc. (NASDAQ:PRME) is one of the best strong buy penny stocks to invest in now. Prime Medicine, Inc. (NASDAQ:PRME) announced on July 8 a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, Inc. relating to the parties’ 2019 Collaboration and License Agreement. The company reported that the Tribunal declared that PM647, […]
Related Links
BEAM Catalysts FAQ
BEAM's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
Upcoming events that could move BEAM include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
BEAM's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
BEAM could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
BEAM could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.